Asperchalasine A selectively inhibits cyclin A, cyclin dependent kinase (CDK) 2, and CDK6 in cancer cells to induce significant cell cycle arrest in the G1 phase [16], suggesting the potential role of asperchalasine A as a promising anti-cancer agent and a selective cell cycle regulator. Here, CCNA2 is linked to cancer.